Stringent patient selection improves outcomes in systemic light-chain amyloidosis after autologous stem cell transplantation in the upfront and relapsed setting

• Christopher P. Venner,
• Julian D. Gillmore,
• Sajitha Sachchithanantham,
• Shameem Mahmood,
• Thirusha Lane,
• Darren Foard,
• Murielle Roussel,
• Lisa Rannigan,
• Simon DJ Gibbs,
• Jennifer H Pinney,
• Carol J. Whelan,
• Helen J. Lachmann,
• Philip N. Hawkins,
• Ashutosh D. Wechalekar

Affiliations

Christopher P. Venner

National Amyloidosis Centre, University College London Medical School, UK;Cross Cancer Institute, University of Alberta, Edmonton, Canada

Julian D. Gillmore

National Amyloidosis Centre, University College London Medical School, UK

Sajitha Sachchithanantham

National Amyloidosis Centre, University College London Medical School, UK

Shameem Mahmood

National Amyloidosis Centre, University College London Medical School, UK

Thirusha Lane

National Amyloidosis Centre, University College London Medical School, UK

Darren Foard

National Amyloidosis Centre, University College London Medical School, UK

Murielle Roussel

Hématologie Clinique, CHU Purpan, Toulouse, France

Lisa Rannigan

National Amyloidosis Centre, University College London Medical School, UK

Simon DJ Gibbs

National Amyloidosis Centre, University College London Medical School, UK;Central Manchester University Hospital, Department of Clinical Haematology, Manchester, UK

Jennifer H Pinney

National Amyloidosis Centre, University College London Medical School, UK

Carol J. Whelan

National Amyloidosis Centre, University College London Medical School, UK

Helen J. Lachmann

National Amyloidosis Centre, University College London Medical School, UK

Philip N. Hawkins

National Amyloidosis Centre, University College London Medical School, UK

Ashutosh D. Wechalekar

National Amyloidosis Centre, University College London Medical School, UK